The challenge of hepatitis C in the HIV-infected person

David L. Thomas

doi:10.1146/annurev.med.59.081906.081110

The challenge of hepatitis C in the HIV-infected person

David L. Thomas

School of Medicine

Research output: Contribution to journal › Review article › peer-review

74 Scopus citations

Abstract

Hepatitis C virus (HCV) coinfection occurs in an estimated one quarter of HIV-infected persons in Europe, Australia, and the United States. As use of highly active antiretroviral drugs has markedly reduced opportunistic infections, HCV-related liver disease has emerged as a leading cause of death. HIV infection adversely affects both the natural history and the treatment of hepatitis C. Because there are no experimental models of coinfection and because the pathogenesis of each infection is incompletely understood, how HIV infection alters hepatitis C is not clear. This review considers the epidemiology, natural history, treatment, and pathogenesis of hepatitis C in HIV-infected persons.

Original language	English (US)
Pages (from-to)	473-485
Number of pages	13
Journal	Annual review of medicine
Volume	59
DOIs	https://doi.org/10.1146/annurev.med.59.081906.081110
State	Published - 2008

Keywords

Coinfection
HCV
Injection drug use
Liver disease

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1146/annurev.med.59.081906.081110

Cite this

@article{d0103adb0d54469eb9c3071520a634c9,

title = "The challenge of hepatitis C in the HIV-infected person",

abstract = "Hepatitis C virus (HCV) coinfection occurs in an estimated one quarter of HIV-infected persons in Europe, Australia, and the United States. As use of highly active antiretroviral drugs has markedly reduced opportunistic infections, HCV-related liver disease has emerged as a leading cause of death. HIV infection adversely affects both the natural history and the treatment of hepatitis C. Because there are no experimental models of coinfection and because the pathogenesis of each infection is incompletely understood, how HIV infection alters hepatitis C is not clear. This review considers the epidemiology, natural history, treatment, and pathogenesis of hepatitis C in HIV-infected persons.",

keywords = "Coinfection, HCV, Injection drug use, Liver disease",

author = "Thomas, {David L.}",

year = "2008",

doi = "10.1146/annurev.med.59.081906.081110",

language = "English (US)",

volume = "59",

pages = "473--485",

journal = "Annual review of medicine",

issn = "0066-4219",

publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - The challenge of hepatitis C in the HIV-infected person

AU - Thomas, David L.

PY - 2008

Y1 - 2008

N2 - Hepatitis C virus (HCV) coinfection occurs in an estimated one quarter of HIV-infected persons in Europe, Australia, and the United States. As use of highly active antiretroviral drugs has markedly reduced opportunistic infections, HCV-related liver disease has emerged as a leading cause of death. HIV infection adversely affects both the natural history and the treatment of hepatitis C. Because there are no experimental models of coinfection and because the pathogenesis of each infection is incompletely understood, how HIV infection alters hepatitis C is not clear. This review considers the epidemiology, natural history, treatment, and pathogenesis of hepatitis C in HIV-infected persons.

AB - Hepatitis C virus (HCV) coinfection occurs in an estimated one quarter of HIV-infected persons in Europe, Australia, and the United States. As use of highly active antiretroviral drugs has markedly reduced opportunistic infections, HCV-related liver disease has emerged as a leading cause of death. HIV infection adversely affects both the natural history and the treatment of hepatitis C. Because there are no experimental models of coinfection and because the pathogenesis of each infection is incompletely understood, how HIV infection alters hepatitis C is not clear. This review considers the epidemiology, natural history, treatment, and pathogenesis of hepatitis C in HIV-infected persons.

KW - Coinfection

KW - HCV

KW - Injection drug use

KW - Liver disease

UR - http://www.scopus.com/inward/record.url?scp=39649113866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39649113866&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.59.081906.081110

DO - 10.1146/annurev.med.59.081906.081110

M3 - Review article

C2 - 18186707

AN - SCOPUS:39649113866

SN - 0066-4219

VL - 59

SP - 473

EP - 485

JO - Annual review of medicine

JF - Annual review of medicine

ER -

The challenge of hepatitis C in the HIV-infected person

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this